

Amendments to the Claims

This listing of claims shall replace all prior versions and listings of claims.

1-29. (Canceled)

30. (Currently Amended) A method of treating an autoimmune disease or condition associated with an autoimmune disease, comprising administering to a patient an effective amount of an isolated polypeptide comprising a first amino acid sequence at least 90% identical to a second amino acid sequence selected from the group consisting of:

- (a) a second polypeptide comprising amino acids 4 to 44 of SEQ ID NO:2;
- (b) a second polypeptide comprising amino acids 4 to 52 of SEQ ID NO:2;
- (c) a second polypeptide comprising amino acids 4 to 54 of SEQ ID NO:2;
- (d) a second polypeptide comprising amino acids 8 to 41 of SEQ ID NO:2;
- (e) a second polypeptide comprising amino acids 1 to 54 of SEQ ID NO:2; and
- (f) a second polypeptide comprising the extracellular domain of the TR18 receptor polypeptide of SEQ ID NO:2;

wherein the autoimmune disease or condition associated with an autoimmune disease is selected from the group consisting of:

- (i) Sjogren's Syndrome; and
- ~~(ii) Reiter's Disease;~~
- ~~(iii) Guillain-Barre Syndrome;~~
- ~~(iv) Hashimoto's thyroiditis;~~
- ~~(v) Addison's disease;~~
- ~~(vi) biliary cirrhosis; and~~
- ~~(vii)~~(ii) asthma.

31. (Previously Presented) The method of claim 30, wherein the isolated polypeptide comprises a first amino acid sequence at least 90% identical to a second amino acid sequence comprising amino acids 4 to 44 of SEQ ID NO:2.

32. (Previously Presented) The method of claim 30, wherein the isolated polypeptide comprises a first amino acid sequence at least 90% identical to a second amino acid sequence comprising amino acids 8 to 41 of SEQ ID NO:2.

33. (Previously Presented) The method of claim 30, wherein the isolated polypeptide comprises a first amino acid sequence at least 90% identical to a second amino acid sequence comprising amino acids 1 to 54 of SEQ ID NO:2.

34. (Previously Presented) The method of claim 30, wherein the isolated polypeptide is post-translationally modified.

35. (Previously Presented) The method of claim 34, wherein the post-translational modification is glycosylation.

36. (Previously Presented) The method of claim 30, wherein the isolated polypeptide is linked to a chemical moiety.

37. (Previously Presented) The method of claim 36, wherein the chemical moiety is polyethylene glycol.

38-39. (Canceled)

40. (Previously Presented) The method of claim 30, wherein the isolated polypeptide further comprises a heterologous amino acid sequence.

41. (Previously Presented) The method of claim 40, wherein said heterologous amino acid sequence is the amino acid sequence of a human immunoglobulin constant domain or fragments thereof.

42. (Previously Presented) The method of claim 30, wherein the autoimmune disease or condition associated with an autoimmune disease is Sjogren's Syndrome.

43. (Currently Amended) The method of claim 30, wherein the autoimmune disease or condition associated with an autoimmune disease is ~~Hashimoto's thyroiditis~~ asthma.

44. (Currently Amended) A method of treating an autoimmune disease or condition associated with an autoimmune disease, comprising administering to a patient an effective amount of an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a polypeptide comprising amino acids 4 to 44 of SEQ ID NO:2;
- (b) a polypeptide comprising amino acids 4 to 52 of SEQ ID NO:2;
- (c) a polypeptide comprising amino acids 4 to 54 of SEQ ID NO:2;
- (d) a polypeptide comprising amino acids 8 to 41 of SEQ ID NO:2;
- (e) a polypeptide comprising amino acids 1 to 54 of SEQ ID NO:2; and
- (f) a polypeptide comprising the extracellular domain of the TR18 receptor polypeptide of SEQ ID NO:2;

wherein the autoimmune disease or condition associated with an autoimmune disease is selected from the group consisting of:

- (i) Sjogren's Syndrome; and
- ~~(ii) Reiter's Disease;~~
- ~~(iii) Guillain Barre Syndrome;~~
- ~~(iv) Hashimoto's thyroiditis;~~
- ~~(v) Addison's disease;~~
- ~~(vi) biliary cirrhosis; and~~
- ~~(vii)~~(ii) asthma.

45. (Previously Presented) The method of claim 44, wherein the isolated polypeptide comprises amino acids 4 to 44 of SEQ ID NO:2.

46. (Previously Presented) The method of claim 44, wherein the isolated polypeptide comprises amino acids 8 to 41 of SEQ ID NO:2.

47. (Previously Presented) The method of claim 44, wherein the isolated polypeptide comprises amino acids 1 to 54 of SEQ ID NO:2.

48. (Previously Presented) The method of claim 44, wherein the isolated polypeptide is post-translationally modified.

49. (Previously Presented) The method of claim 48, wherein the post-translational modification is glycosylation.

50. (Previously Presented) The method of claim 44, wherein the isolated polypeptide is linked to a chemical moiety.

51. (Previously Presented) The method of claim 50, wherein the chemical moiety is polyethylene glycol.

52-53. (Canceled)

54. (Previously Presented) The method of claim 44, wherein the isolated polypeptide further comprises a heterologous amino acid sequence.

55. (Previously Presented) The method of claim 54, wherein said heterologous amino acid sequence is the amino acid sequence of a human immunoglobulin constant domain or fragments thereof.

56. (Previously Presented) The method of claim 44, wherein the autoimmune disease or condition associated with an autoimmune disease is Sjogren's Syndrome.

57. (Currently Amended) The method of claim 44, wherein the autoimmune disease or condition associated with an autoimmune disease is Hashimoto's thyroiditis asthma.